2024 reported sales
USD 29.482BSource: Merck 2024 Annual Report Pharmaceutical commercial intelligence
Keytruda Commercial Intelligence Report
Examine Keytruda sales, treatment-setting competition, Qlex strategy and lifecycle questions.
Sales history · Treatment-setting competition · Formulation strategy · Lifecycle review
Sample-period growth
+17.9%↗ Calculated
2023 to 2024Revenue-tool history
2015–2025Worldwide Merck-reported annual sales; USDAt a glance
Keytruda commercial snapshot
2015'16'17'18'19'20'21'22'23'242025
2035
+17.9%Calculated change
2023 → 2024
2023 → 2024
Source: Merck 2023 Annual Report; Merck 2024 Annual Report.
Explore the public sampleHistorical bars show relative movement only. Illustrative only; this range is not a year-specific or validated forecast. Confirm the edition’s forecast scope and assumptions with Lucentra. The 2025 line in Merck’s annual product-sales table combines Keytruda and Keytruda Qlex. The 2025 observation is currently supported by one annual filing.
Source: Merck annual reports; Lucentra Revenue Tool.
Product profile
Pembrolizumab
Merck’s anti-PD-1 cancer immunotherapy; Qlex is reviewed as a separate subcutaneous formulation.
Competitive context
Treatment-setting view
The report compares relevant therapies by setting, comparator and clinical endpoint; it does not imply one universal market-share ranking.
Lifecycle watch
Formulation and entry questions
Qlex’s approval and the protection landscape are assessed separately; a patent date alone does not establish a market-entry date.
Report overview
Keytruda sales, competition and lifecycle context
Keytruda (pembrolizumab) is Merck’s anti-PD-1 cancer immunotherapy. This report connects the product’s reported sales with competition in selected treatment settings, regulatory expansion, formulation strategy and lifecycle questions.
Merck reported worldwide Keytruda sales of USD 25.011 billion in 2023 and USD 29.482 billion in 2024, a calculated increase of 17.9%. Merck’s 2025 annual product-sales line combines Keytruda and Qlex, so the product boundary changes in the latest year and is identified in the revenue preview.
2024 sales rose 17.9%
Calculated from Merck-reported worldwide sales of USD 25.011 billion in 2023 and USD 29.482 billion in 2024.
Qlex adds a subcutaneous option
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection on 19 September 2025; the report examines its commercial role separately from IV sales.
Entry timing depends on more than one date
The analysis considers patent context, biosimilar readiness, litigation and formulation strategy without treating a patent expiry as a guaranteed launch date.
EvidenceMerck 2025 Annual Report
Sample from Lucentra’s revenue tool
Keytruda sales data
Worldwide Merck-reported annual sales; USD. Two annual values are shown as a public sample; other listed years are masked.
| Year | Reported sales (USD million) | Access |
|---|---|---|
| 2022 | Masked in preview | Full dataset |
| 2023 | 25,011 Source: Merck 2023 Annual Report | Public sample |
| 2024 | 29,482 Source: Merck 2024 Annual Report | Public sample |
| 2025 | Masked in preview | Full dataset |
The full annual history opens in Lucentra’s revenue platform. Check product boundaries and source status by year.
Explore the full reported history.
Open revenue data Open the existing revenue tool with Keytruda selected. Platform access and report access are separate.
Inside the research
What the Keytruda report covers
The report brings sales performance together with the competitive, regulatory and lifecycle questions relevant to this product. Final edition, geography and deliverables are confirmed by enquiry.
- 01
Product identity and formulation strategy
Pembrolizumab’s commercial role, the reporting boundary between IV Keytruda and Qlex, and the implications of subcutaneous delivery.
- 02
Sales trajectory and reporting scope
Annual company-reported sales, calculated growth and the product-boundary changes that affect comparisons over time.
- 03
Indications and regulatory milestones
Selected label expansions and dated milestones, with geography, setting and source evidence kept explicit.
- 04
Competitors and clinical differentiation
Relevant checkpoint inhibitors and emerging approaches compared within specified treatment settings, populations and endpoints.
- 05
Development pipeline and combinations
Selected combination programs and development outcomes, with uncertainty and discontinued work identified.
- 06
Patents, exclusivity and biosimilars
Protection context, biosimilar development and litigation questions; listed patent dates are not presented as guaranteed launch dates.
- 07
Access, reimbursement and lifecycle risks
Selected access and reimbursement considerations, including unresolved questions that could affect formulation adoption.
- 08
Commercial implications and evidence
The drivers, risks, source notes and evidence gaps that matter when assessing the report’s conclusions.
Commercial questions
Questions this research examines
- How should the Keytruda and Qlex reporting boundary be handled when comparing annual sales?
- Which therapies are relevant in the treatment settings covered by this report?
- How could formulation strategy, access and potential competitive entry affect the franchise?
Before you choose
Report scope and access
- Primary product
- Keytruda (pembrolizumab); Qlex discussed with its reporting boundary identified
- Commercial focus
- Oncology sales, competition, formulation and lifecycle strategy
- Revenue coverage
- 2015–2025 available annual history; latest source status appears in the chart note
- Geography
- Worldwide reported sales; selected US and European regulatory and lifecycle context
- Forecast status
- No validated numerical forecast is presented in this preview
- Report format
- Confirmed with the requested edition and scope
- Access
- Sample and quotation by enquiry; final licence, price and delivery confirmed before purchase
The final quotation confirms included content, file formats, licence and delivery.
Next steps
How to get this report
Choose the level of detail that fits your decision. Lucentra confirms availability, scope and terms with you before purchase.
01
Request a sample
Ask for selected pages and the approved public data sample so you can assess the coverage and evidence style.
Request a sample02
Confirm the report scope
Review the edition, included analysis, file formats and licence. Lucentra confirms the quotation and delivery details before purchase.
Request report details03
Tailor the research
Share the markets, competitors or commercial questions that matter to your decision; requested additions are confirmed separately.
Discuss a custom scopeEvidence you can inspect
Methodology and sources
The public sales sample is reconciled with Merck annual filings. Company-reported amounts remain separate from calculated growth and analytical interpretation. The 2025 reported line combines Keytruda and Qlex and is currently supported by one annual filing. Competitive, regulatory and lifecycle statements retain the cited scope; material gaps and unresolved assumptions are identified.
Merck 2023 Annual Report
Source: Merck & Co., Inc. / SEC · Keytruda reported annual sales for 2023.
Merck 2024 Annual Report
Source: Merck & Co., Inc. / SEC · Keytruda reported annual sales for 2024; growth shown on this page is calculated.
Merck 2025 Annual Report
Source: Merck & Co., Inc. · 2025 product-sales boundary, including Keytruda and Qlex, and lifecycle context.
FDA approval notice for subcutaneous Keytruda Qlex
Source: US Food and Drug Administration · Approval dated 19 September 2025; uses are subject to the approved label.
Research information reviewed 2026-10-20. Research cutoffs and subsequent updates are confirmed for the requested edition.
Useful answers
Keytruda report FAQs
What does the Keytruda report cover?
It connects reported sales with treatment-setting competition, regulatory developments, formulation strategy, biosimilar exposure and lifecycle questions. The exact scope and deliverables are confirmed for the requested edition.
Are the sales figures Keytruda-only or the full franchise?
The public 2023 and 2024 samples are Merck-reported Keytruda sales. Merck’s 2025 annual product-sales line combines Keytruda and Qlex, and the preview identifies that boundary.
Does the chart show a numerical forecast to 2035?
No. The future shaded band is an illustrative visual around the latest reported year, with no forecast values or scale displayed. It is not a year-by-year model output.
Can I open the complete sales history?
Use the revenue-platform link to open Keytruda in Lucentra’s existing tool. Account access and the platform’s current allowances apply. Platform access and a research report are separate products.
How do I request the report?
Request a sample or quotation through the enquiry options. Lucentra confirms the edition, scope, included files, licence, price and delivery before purchase; this page does not offer instant checkout.
Start with your research question
Review the Keytruda report scope
Request a sample, confirm the edition and discuss any additional coverage you need.